The ErbB3 binding protein EBP1 ...
The ErbB2/3 heterodimer plays a critical role in breast cancer progression and in the development of endocrine resistance. EBP1, an ErbB3 binding pr ...
Aromatase inhibitor therapy: to ...
Aromatase inhibitors (AIs) have been shown to reduce the risk of breast cancer recurrence and are widely used today as adjuvant therapy in women wit ...
Large genomic rearrangements of ...
Germline mutations in BRCA1 and BRCA2 increase the risk for developing breast and ovarian cancer. Previously, the techniques available allowed only ...
Accumulation of mutations over ...
The occurrence of heteroplasmy and mixtures is technically challenging for the analysis of mitochondrial DNA. More than that, observed mutations nee ...
Management of radial sclerosing ...
Background Radial sclerosing lesions (RSLs) of the breast are benign lesions that can mimic carcinoma on mammography and are frequently associated w ...
Involvement of PKC delta (PKCd) ...
Doxorubicin is an anti-tumor antibiotic widely used in the management of cancer patients. Its main mechanism of action involves the generation of DN ...
Ionizing radiation or mitomycin ...
BRCA1 and BRCA2 genes are essential in preserving the integrity of genome, and it is not unambiguously clear whether the heterozygosity status may a ...
Axillary lymph node dissection ...
Evaluation of axillary lymph node status by sentinel lymph node biopsy (SLNB) and complete axillary lymph node dissection (ALND) are an inherent par ...
Triple negative breast cancer: ...
Triple negative breast cancer (TNBC) is an aggressive clinical phenotype characterized by lack of expression (or minimal expression) of estrogen rec ...
Overexpression of HER2 signalin ...
The final signal for triggering the formation of lamellipodia that initiate directional migration of mammalian cells is binding of the Wiskott–Aldri ...
Amplification of the prolactin ...
The identification of lobular carcinoma in situ (LCIS) in a patient’s specimen confers an appreciable increased risk of development of future invasi ...
CD36-mediated activation of end ...
Thus far the clinical benefits seen in breast cancer patients treated with drugs targeting the vascular endothelial growth factor (VEGF) pathway are ...
Detection of circulating tumor ...
Most assays to detect circulating tumor cells (CTCs) rely on EpCAM expression on tumor cells. Recently, our group reported that in contrast to other ...
Amplification of ESR1 may predi ...
The estrogen receptor (ER) is the target of tamoxifen, but endocrine therapies do not benefit all patients with ER positive tumors. We therefore hyp ...
The b2-adrenergic receptor and ...
In this study, b2-AR level was found to be up-regulated in MCF-7 cells overexpressing Her2 (MCF-7/ Her2). Correlation of b2-AR level with Her2 statu ...
Estrogen levels act as a rheost ...
A large proportion of breast cancers expresses the estrogen receptor alpha (ERa) and are dependent on estrogens for their proliferation and survival ...
A systematic review of the rela ...
The estrogen signal is mediated by the estrogen receptor (ER). The specific role of ER-beta, a second ER, in breast carcinogenesis is not known. A n ...
Pathways mediating the effects ...
Invasion and metastasis of aggressive breast cancer cells are the final and fatal steps during cancer progression. Clinically, there are still limit ...
Selective and effective killing ...
The cell surface receptor tissue factor (TF) is regarded as a common but specific target on angiogenic tumor vascular endothelial cells (VECs) and t ...
Elevated TRF2 in advanced breas ...
Telomere repeat binding factor 2 (TRF2) binds directly to telomeres and preserves the structural integrity of chromosome ends. In vitro models sugge ...
Toremifene is an effective and ...
Compared to tamoxifen, the efficacy and side effects of toremifene in adjuvant endocrine therapy for breast cancer were not very clear. This meta-an ...
Ep-CAM RNA expression predicts ...
Epithelial cell adhesion molecule (Ep-CAM) recently received increased attention as a prognostic factor in breast cancer.We aimed to validate the in ...
Hypermethylation of the progest ...
Most breast carcinomas that are estrogen receptor (ER) and progesterone receptor (PR) positive respond initially to an endocrine therapy, but over t ...
Trastuzumab-DM1 (T-DM1) retains ...
Trastuzumab (Herceptin) is currently used as a treatment for patients whose breast tumors overexpress HER2/ErbB2. Trastuzumab-DM1 (T-DM1, trastuzum ...
PALB2 analysis in BRCA2-like fa ...
BRCA2 and PALB2 function together in the Fanconi anemia (FA)–Breast Cancer (BRCA) pathway. Mono-allelic and bi-allelic BRCA2 and PALB2 mutation car ...